Comparison of intravenous efgartigimod and intravenous immunoglobulin in patients with Guillain-Barré syndrome.

Orphanet J Rare Dis · 2025 · PMC12542069 · PMID 41121372

Europe PMC DOI

hedged sentence

0.0070

closest p · 0.1× alpha

0.0070

boldest claim

The sentences

did not reach statistical significanceP = 0.007actually significant

Although most secondary outcomes did not reach statistical significance, the MRC sum score demonstrated significantly greater improvement in the efgartigimod cohort than in the IVIg cohort ( P = 0.007).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.